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ABSTRACT
Anticancer therapy is always known to cause various side effects. L-asparaginase used in the treatment of adult T-cell lymphoblastic leukemia is a 
novel class of drug, an enzyme produced from plants as well as microorganisms except human. It is known to cause various adverse reactions including 
life-threatening neurological complications and thrombotic disorders. Hence, we report a case of hypofibrinogenemia associated with L-asparaginase 
in a patient treated for T-cell adult lymphoblastic leukemia.
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INTRODUCTION
L-asparaginase is a novel chemotherapeutic agent present obtained 
from various plants, bacteria, fungus except humans. It is used in 
the treatment of adult as well as pediatric lymphoblastic leukemia. 
L-asparaginase enzyme plays a very crucial role in the production 
of aspartate family of amino acids, namely, threonine, lysine, and 
methionine. L-asparaginase is known to cause severe thrombotic 
complications. Hence, we report a case of L-asparaginase-induced 
hypofibrinogenemia in a 16-year-old male, T- cell adult lymphoblastic 
leukemia (ALL) patient in a tertiary care hospital in South India
CASE REPORT
Informed consent was taken from the patient. A 16-year-old male 
patient diagnosed of ALL of T-cell type on September 09, 2016 and was 
started on September 10, 2016, with injection vincristine 2 mg and 
injection daunorubicin 64 mg. After completion of the first cycle with 
above two drugs, the second cycle was started with L-asparaginase on 
October 02, 2016, at a dose of 16,000 IU/m2 along with vincristine and 
daunorubicin. The latter two drugs were given on the same day once at 
the dose as used in the first cycle. L-asparaginase was continued, and 
after 10 days on October 13, 2016, patient’s routine blood investigation 
revealed a drop in fibrinogen levels to a very low level of 67.6 mg/dl. 
Other laboratory parameters were normal, and liver function test was 
also normal. There was no bleeding or thrombotic events, and finally, 
L-asparaginase was suspected to be the cause, and other causes were 
ruled out. L-asparaginase was stopped on October 19, 2016, and the 
patient’s fibrinogen assay returned to normal levels on October 20, 
2016 (Table 1).
DISCUSSION
L-asparaginase is a tetrameric protein, and it plays a pivotal role 
in the hydrolysis of free L-asparaginase enzyme into aspartic acid 
and ammonia [1]. L-asparaginase enzyme accounts for almost 40% 
worldwide sale as a potential therapeutic antileukemic agent [2]. 
It is also used in the treatment of Hodgkin’s lymphoma, chronic 
lymphocytic leukemia, and melanosarcoma as antineoplastic 
agent apart being a novel class of drug used in the treatment of 
adult T-cell lymphoblastic leukemia. Mashbrun and Wriston first 
isolated L-asparaginase from Escherichia coli, and this kick started 
the production of this enzyme in large scale for the treatment of 
leukemia [2].
An interesting mechanism of L-asparaginase has made it the blockbuster 
agent in the treatment of leukemia. The mechanism of action is, as 
cancer cells are dependent on exogenous supply of asparagine, due 
to lack of L-asparaginase synthetase enzyme; when L-asparaginase is 
given therapeutically in leukemic patients, this drug drains out all the 
available asparagine, and later cancer cells starve to death due to the 
lack of asparagine [3]. L-asparaginase is known to cause various side 
effects due to its effect on normal body cells which includes hepatic 
dysfunction, skin rashes, breathlessness, acute pancreatitis, leucopenia, 
thrombosis, hemorrhage, depression, seizures, fatigue, and severe 
neurological toxicity [3].
Hypofibrinogenemia, defined as fibrinogen levels below 150 mg/dl, 
can be caused by both congenital as well as acquired causes. Congenital 
abnormalities include Type I afibrinogenemia which is caused by 
mutations in both chromosomal alleles of fibrinogen gene whereas 
Type II dysfibrinogenemia is basically due to mutations in one 
chromosomal allele of fibrinogen gene [4,5]. Acquired causes include 
reduced synthesis due to liver disease, increased consumption due 
to sepsis, cancer, and tissue plasminogen activator therapy, and 
hemodilution due to massive transfusions and due to autoantibody 
against fibrinogen in case of autoimmune diseases [6]. Many drugs 
are also known to cause hypofibrinogenemia including prednisolone, 
alteplase, tigecycline, isotretinoin therapy, autoantibodies 
produced due to isoniazid, and also bovine fibrin glue used in 
surgeries. There are case reports of hypofibrinogenemia induced by 
L-asparaginase [7]. Mechanism attributed to this adverse reaction is 
mainly decreased synthesis of fibrinogen, and rapid death of cancer 
cells may also contribute to fall in fibrinogen levels due to consumption 
coagulopathy [7].
In our case, the patient was diagnosed of adult T-cell lymphoblastic 
leukemia and was started with vincristine and daunorubicin. At the 
end of first cycle, fibrinogen levels were normal. After induction of 
L-asparaginase in the second cycle, the patient showed decreased 
fibrinogen levels after 10 days of starting the treatment. Hence, 
with this evidence by ruling out other potential acquired as well as 
congenital causes of hypofibrinogenemia, L-asparaginase was found 
to be causative agent of decreased fibrinogen levels in the study 
patient. Furthermore, after stopping the drug, the patient recovered 
back immediately supporting our finding. Hence, to establish a causal 
relationship, causality assessment using Naranjo’s scale [8] was 
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performed, and a probable causal relationship was ascribed. Severity 
scale was performed using Hartwig’s scale [9], and adverse reaction was 
found to be of mild severity. Furthermore, preventability assessment 
was done as per Thornton’s scale [10], and adverse reaction was found 
to be not preventable (Table 2).
CONCLUSION
L-asparaginase, a very useful drug in the treatment of leukemia causes 
many adverse reactions and hypofibrinogenemia, is one among them. 
Severe hypofibrinogenemia can lead to life-threatening complications 
in some patients. Hence, proper monitoring of fibrinogen levels 
using fibrinogen assays is of at most importance, and further clinical 
studies can be performed to find the incidence of hypofibrinogenemia 
associated with L-asparaginase treatment in leukemia patients.
REFERENCES
1. Thandeeswaran M, Mahendran R, Kiran K, Nawa K, Palaniswamy M, 
Jayaraman A. Screening and production of anticarcinogenic enzyme 
from Escherichia coli CTLS20: L - Asparaginase. Int J Pharm Pharm 
Sci 2016;8(3):244-8.
2. Kumar R, Sedolkar V, Triveni A, Kumar M, Shivannavar C, Gaddad S. 
Isolation, screening and characterization of L-asparaginase producing 
fungi from medicinal plants. Int J Pharm Pharm Sci 2015;8(1):281-3.
3. Batool T, Makky EA, Jalal M, Yusoff MM. A comprehensive review 
on L-asparaginase and its applications. Appl Biochem Biotechnol 
2016;178(5):900-23.
4. Bolton-Maggs PH, Perry DJ, Chalmers EA, Parapia LA, Wilde JT, 
Williams MD, et al. The rare coagulation disorders - Review with 
guidelines for management from the United Kingdom Haemophilia 
Centre Doctors’ Organisation. Haemophilia 2004;10(5):593-628.
5. Roberts HR, Stinchcombe TE, Gabriel DA. The dysfibrinogenaemias. 
Br J Haematol 2001;114(2):249-57.
6. Besser MW, MacDonald SG. Acquired hypofibrinogenemia: Current 
perspectives. J Blood Med 2016;7:217-25.
7. Bettigole RE, Himelstein ES, Oettgen HF, Clifford GO. 
Hypofibrinogenemia due to L-asparaginase: Studies of fibrinogen 
survival using autologous 131-I-fibrinogen. Blood 1970;35(2):195-200.
8. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. 
A method for estimating the probability of adverse drug reactions. Clin 
Pharmacol Ther 1981;30(2):239-45.
9. Hartwig SC, Siegel J, Schneider PJ. Preventability and severity 
assessment in reporting adverse drug reactions. Am J Hosp Pharm 
1992;49(9):2229-32.
10. Schumock GT, Thornton JP. Focusing on the preventability of adverse 
drug reactions. Hosp Pharm 1992;27(6):538.
Table 1: Fibrinogen levels before and after L‑asparaginase
Date Fibrinogen levels (mg/dl)
September 30, 2016 306
October 04, 2016 167
October 13, 2016 67.6
October 20, 2016 208.7
Table 2: Adverse drug assessment
Scales Assessment
Naranjo’s Probable
Hartwig’s Mild severity
Thornton’s Not preventable
